Managing Nonadvanced Systemic Mastocytosis

Program Description

Nonadvanced systemic mastocytosis (SM) is characterized by the accumulation of mast cells in extracutaneous organs, with or without skin involvement. This disorder is difficult to diagnose and manage due to the wide variety of symptoms, anaphylactic triggers, and complicated treatment paradigm that requires individualization based on each patient’s presentation. Join us for an engaging Expert Roundtable discussion to gain multidisciplinary insights into diagnosis and management strategies for nonadvanced SM and learn about invaluable patient resources that are available.

Target Audience

This activity is designed to educate a primary audience of clinical immunologists, allergists, dermatologists, and other attendees who manage patients with nonadvanced SM.

Educational Objectives

1. Explain the underlying pathophysiology of nonadvanced SM, including the effects of driver mutations on mast cell (MC) hyperactivation and the rationale for new targeted therapies
2. Use World Health Organization (WHO) criteria to differentially diagnose nonadvanced SM and classify subtype based on symptoms, biomarkers, and genetic testing results
3. Describe recent clinical trial evidence for new and emerging targeted treatment options, including FDA-approved therapies
4. Create individualized treatment plans reflecting clinical evidence for treatment efficacy and safety, patient-reported outcomes, and shared decision-making
5. Educate patients with nonadvanced SM on support resources available, including those provided by The Mast Cell Disease Society (TMS)

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pretest, posttest, and program evaluation.

Disclosures of Conflicts of Interest

Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Matthew P. Giannetti, MD: Consulting, medical safety board: Cogent Biosciences, Inmagene; Research funding: Blueprint Medicines Corporation

Lauren M. Madigan, MD: Consulting Fees: Blueprint Medicines Corporation; Other: JAMA Dermatology (co-section editor)

Anton Rets, MD: Consulting Fees: Blueprint Medicines Corporation

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For questions about this activity, please contact us at info@exchangecme.com.